European Journal of Heart Failure

JANUARY 17, 2025

A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end-organ dysfunction.

Cardiogenic Shock 75

Cardiogenic Shock Biomarkers Pharmacology Circulation 75

Dr. Smith's ECG Blog

NOVEMBER 19, 2016

Author continued : STE in aVR is often due to left main coronary artery obstruction (OR 4.72), and is associated with in-hospital cardiovascular mortality (OR 5.58). Authors' commentary: Cardiogenic shock in the setting of severe aortic stenosis. Fundamentally, cardiogenic shock is an issue of decreased cardiac output.

Ischemia 40

Ischemia Cardiogenic Shock Aortic Stenosis 40

Journal of the American Heart Association

FEBRUARY 23, 2024

BackgroundThe effects of pharmacological therapy on cardiogenic shock (CS) survivors have not been extensively studied. Of 772 patients, 535 patients were enrolled in the present analysis following the exclusion of 217 in‐hospital deaths and 20 patients with missing medical records.

Cardiogenic Shock 40

Cardiogenic Shock Heart Failure Pharmacology Hospital 40